bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics

bioAffinity Technologies announced a collaboration with Pictor to develop next‑generation, high‑throughput diagnostics for asthma and COPD.Key Highlights:Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 8-K - Jul. 22, 2026This is an AI-powered summary. It may contain inaccuracies. Con…

bioAffinity Technologies announced a collaboration with Pictor to develop next‑generation, high‑throughput diagnostics for asthma and COPD.

Key Highlights:

bioAffinity will integrate its flow cytometry sputum platform with Pictor’s targeted proteomic analysis to profile airway inflammation.
Collaboration aims to increase lab throughput and lower operating costs versus single‑analyte testing, enabling scalable LDT offerings.
bioAffinity will own IP from the collaboration; Pictor retains and owns inventions related to its proteomic platform.
Initial tests are expected to be offered as CLIA Laboratory Developed Tests to help match patients to targeted therapies and biologics.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.